OBOT vs OTP: How Office-Based and Program-Based Opioid Treatment Differ

What is OBOT?

OBOT — office-based opioid treatment — is the term for prescribing medications for opioid use disorder in standard outpatient medical settings. A patient sees a physician, nurse practitioner, or physician assistant in a regular medical office; receives a prescription for buprenorphine or naltrexone; and follows up on a routine outpatient cadence (typically weekly during induction, then monthly during maintenance).

The medications available under OBOT include:

• Suboxone — daily sublingual film or tablet combining buprenorphine and naloxone
• Sublocade — once-monthly subcutaneous extended-release buprenorphine injection
• Brixadi — subcutaneous buprenorphine injection with weekly, bi-weekly, or monthly dosing schedules
• Vivitrol — once-monthly intramuscular naltrexone (an opioid antagonist; at Restoration Recovery, Vivitrol is used only for alcohol use disorder)
• Oral naltrexone — daily tablet (less commonly first-line for opioid use disorder)

Visit cadence in OBOT is set by the prescribing clinician based on clinical need and federal/state requirements, not by federal regulation. Initial visits are typically weekly during induction; once a patient is stable on a maintenance dose, follow-up shifts to every two to four weeks during the first year, then monthly. The Tennessee BESMART program, which Restoration Recovery participates in, requires office visits at least every two months during stable buprenorphine maintenance for TennCare members.

Regulatory framework: post-MAT Act 2023, any DEA-registered practitioner can prescribe buprenorphine for opioid use disorder. The previously-required X-waiver was eliminated by Section 1262 of the Consolidated Appropriations Act 2023. Privacy is governed by 42 CFR Part 2 (the federal substance use treatment confidentiality rule) on top of HIPAA.

What is an OTP?

An OTP — opioid treatment program — is a SAMHSA-certified specialty clinic that dispenses methadone for opioid use disorder under federal regulation. Some OTPs also offer buprenorphine and naltrexone, but the defining feature is that OTPs are the only setting where methadone for opioid use disorder is dispensed in the United States.

OTPs operate under 42 CFR Part 8, the regulation governing certification and operation of opioid treatment programs. The framework specifies:

• SAMHSA certification of the program (separate from individual physician licensure)
• DEA registration as a Narcotic Treatment Program (Schedule II)
• State opioid treatment authority approval
• Federally mandated counseling integration (initial assessment, treatment plan, ongoing counseling at specified intervals)
• Drug screening at federally specified frequencies
• Take-home dosing privileges granted on a graduated schedule based on documented stability

The core OTP visit pattern is daily on-site attendance for methadone dosing in early treatment. Federal regulations were updated by SAMHSA's 2024 final rule to expand take-home flexibility — up to 28 days take-home methadone is now permissible for stable patients, compared to the previous 30-day post-induction maximum of six days under the prior rule. Counseling, drug screening, and program rules continue to be more structured in OTPs than in OBOT settings.

Telehealth in OTPs: the 2024 final rule expanded telehealth flexibility for initial evaluation in some circumstances, but methadone for opioid use disorder still requires in-person dosing under federal law. Buprenorphine in an OTP can be initiated and maintained via telehealth following the same DEA rule that applies to OBOT.

Side-by-side: OBOT vs OTP

The table below summarizes how the two pathways differ across the variables that most affect a patient's day-to-day experience and clinical fit.

Who fits OBOT, who fits an OTP?

The right pathway depends on patient profile, medication response history, life circumstances, and clinical judgment. The two lists below describe typical patient profiles for each pathway based on SAMHSA TIP 63, the ASAM National Practice Guideline, and current clinical practice.

Patients typically best served by OBOT

• Most patients with opioid use disorder — including severe OUD, fentanyl exposure, prescription-pill dependence, and kratom or 7-OH dependence
• Work, family, or caregiving obligations that make daily clinic visits impractical
• Geographic distance to the nearest OTP — common across rural Tennessee and North Georgia, where OTPs concentrate in larger metros
• Preference for medical-office privacy — OBOT visits look like routine primary-care appointments to anyone who might see a patient's calendar or parking
• Buprenorphine-responsive treatment history — per Mattick 2014 Cochrane, retention rates for buprenorphine maintenance approximate methadone retention at adequate doses, and the majority of patients who initiate on buprenorphine maintain remission
• Telehealth-friendly: post-2025 DEA rule, OBOT follow-up visits can be scheduled remotely, which expands access for patients with mobility, transportation, or childcare constraints

Patients typically best served by an OTP

• Severe opioid use disorder with very high tolerance who have not responded to thoughtful high-dose buprenorphine, including long-acting injectables and dose optimization — a small subset, not the typical OUD patient
• Multiple thoughtful buprenorphine attempts (including long-acting injectables) without stable response — methadone's full-agonist pharmacology can succeed in the smaller cohort where buprenorphine has not
• Patient preference for methadone specifically — some patients have prior positive experience with methadone or feel it fits their physiology better than buprenorphine
• State or insurance factors — some Medicaid programs route patients to OTPs based on treatment-history criteria

Importantly, OBOT and OTP are not mutually exclusive over time. Patients can transition from OBOT to OTP if buprenorphine is not adequate; patients on OTP methadone often transition to OBOT buprenorphine after stability for the lifestyle benefits. The ASAM National Practice Guideline treats both pathways as first-line options for opioid use disorder; the difference is clinical fit, not hierarchy.

Privacy under 42 CFR Part 2

Both OBOT and OTP are subject to 42 CFR Part 2, the federal regulation governing confidentiality of substance use treatment records. Part 2 is stricter than HIPAA: records cannot be disclosed to family members, employers, other healthcare providers, or law enforcement without the patient's specific written consent (with narrow exceptions for medical emergencies, audits, and court orders).

SAMHSA's 2024 Part 2 Final Rule aligned some Part 2 provisions with HIPAA — specifically, single patient consent now permits ongoing record sharing for treatment, payment, and operations (TPO), comparable to HIPAA's general consent framework. But the core protections remain in 2026: the ban on disclosure to law enforcement without a court order, the protection of records in custody and parental disputes, and the right to consent before specific disclosures outside of TPO.

Practical impact: a patient at Restoration Recovery's Chattanooga clinic has the same Part 2 privacy protection as a patient at a methadone OTP. The visible difference is in setting — OBOT visits are indistinguishable from primary-care visits to outside observers, while OTP visits at a standalone methadone clinic are more identifiable as substance use treatment.

How regulations changed: MAT Act 2023 + DEA telehealth rule

Two recent federal changes reshaped the OBOT pathway specifically:

MAT Act 2023 (Section 1262 of the Consolidated Appropriations Act 2023) eliminated the X-waiver, the previously-required special DEA registration for buprenorphine prescribing. Before the MAT Act, physicians needed an X-waiver — with patient caps of 30, 100, or 275 depending on registration level — to prescribe buprenorphine for opioid use disorder. After January 2023, any DEA-registered practitioner can prescribe buprenorphine without a special waiver and without patient caps. The result: substantial expansion of OBOT access, especially in rural areas where the X-waiver had been a major bottleneck.

DEA permanent buprenorphine telehealth rule (2025), published in the Federal Register, made permanent the COVID-era flexibility allowing buprenorphine prescribing via audio-video telehealth without a prior in-person evaluation. OBOT clinics can now initiate patients via telehealth and maintain them via telehealth follow-up under permanent law. This is a structural advantage of the OBOT pathway that is not currently available for methadone in OTPs.

OTP regulations were updated in 2024 (the SAMHSA final rule) to expand take-home methadone flexibility and modernize counseling requirements, but the structural requirement for in-person methadone dosing in early treatment remains. The OTP framework was designed for a different kind of treatment intensity, and 42 CFR Part 8 continues to reflect that.

Restoration Recovery and OBOT

Restoration Recovery is an OBOT provider. Across our four clinics — Chattanooga, Cleveland, Soddy-Daisy, and Ringgold — we provide buprenorphine-based treatment for opioid use disorder (Suboxone, Sublocade, Brixadi), naltrexone (Vivitrol) for alcohol use disorder, and Acamprosate for alcohol abstinence maintenance. We also offer Intensive Outpatient Programming, telehealth follow-ups, and integrated Hepatitis C care at the Chattanooga clinic.

We do not operate as an OTP and do not dispense methadone. Patients whose clinical situation is best served by methadone can find SAMHSA-certified opioid treatment programs through SAMHSA's Find Treatment locator. Both pathways are evidence-based; the right choice for any given patient depends on the clinical situation, not on a hierarchy of treatment quality.

For a closer look at the medications themselves — how methadone and buprenorphine compare on pharmacology, efficacy, safety, and clinical fit — see our companion guide on Methadone vs Suboxone.

Frequently asked questions

Is OBOT or OTP better for opioid use disorder?

Neither pathway is uniformly better. Both OBOT with buprenorphine and OTP with methadone are evidence-based first-line treatments. Sordo et al. (BMJ 2017) found both medications reduce all-cause mortality by approximately 50 to 75 percent compared to no treatment, with overlapping confidence intervals. The right pathway depends on patient profile, medication response, life circumstances, geographic access, and clinical judgment.

Why doesn't Restoration Recovery offer methadone?

Restoration Recovery operates as an OBOT clinic, not an OTP. Methadone for opioid use disorder can only be dispensed at SAMHSA-certified OTPs under 42 CFR Part 8. Our four clinics provide buprenorphine-based MAT (Suboxone, Sublocade, Brixadi) and naltrexone (Vivitrol for alcohol use disorder), which together cover the medication needs of most adults with opioid use disorder. Patients whose situation is best served by methadone can find OTPs through findtreatment.gov.

Can I switch from OTP methadone to OBOT buprenorphine later?

Yes. Transitioning from methadone to buprenorphine is a routine clinical pathway. The transition typically requires a medical taper of methadone to a low dose (commonly 30 milligrams or less daily), then a structured switch to buprenorphine when the patient is in mild withdrawal. Some teams use micro-induction protocols to bridge the transition without a full methadone taper. Many patients moving from OTP to OBOT find buprenorphine's once-monthly injection options (Sublocade, Brixadi) particularly attractive after years of daily methadone dosing.

Does insurance cover OBOT and OTP equally?

TennCare and Medicare cover both. Most commercial plans cover OBOT (office visits and medication) under standard medical benefits and OTP (bundled program fees) under behavioral health or substance use treatment benefits. Coverage details vary by plan: OBOT typically applies office-visit copays plus medication tier formulary rules; OTP is usually a bundled per-day or per-month rate. Restoration Recovery's intake team verifies coverage before the first visit; for OTP-specific coverage, contact the prospective program or your insurance plan directly.

Can I start OBOT via telehealth?

Under the DEA's permanent buprenorphine telehealth final rule of 2025, audio-video telehealth can be used to evaluate and prescribe buprenorphine for opioid use disorder without a prior in-person visit. Restoration Recovery's first visit is in-person to allow a thorough physical evaluation, urine drug screen, and DEA-compliant induction; many follow-up visits can then be scheduled via telehealth. Methadone in OTPs still requires in-person dosing under federal law.

I am pregnant. Does OBOT or OTP fit better?

Both methadone and buprenorphine are evidence-based and recommended for opioid use disorder during pregnancy by the American College of Obstetricians and Gynecologists and SAMHSA. Methadone has the longer track record. Buprenorphine has a growing evidence base and may produce less severe neonatal abstinence syndrome. The right choice is a clinical conversation between the patient, the addiction medicine team, and obstetric care; geographic access and continuity of care often play significant roles. Pregnant patients considering buprenorphine via OBOT should plan coordinated obstetric care; pregnant patients considering methadone should be referred to a SAMHSA-certified OTP.

Sources and references

1. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550.
2. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, Issue 2.
3. Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series.
4. American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder — 2020 Focused Update.
5. Code of Federal Regulations. 42 CFR Part 8: Medication Assisted Treatment for Opioid Use Disorders. Substance Abuse and Mental Health Services Administration.
6. Code of Federal Regulations. 42 CFR Part 2: Confidentiality of Substance Use Disorder Patient Records.
7. Substance Abuse and Mental Health Services Administration. Final Rule: Medications for the Treatment of Opioid Use Disorder. Federal Register, February 2, 2024.
8. Substance Abuse and Mental Health Services Administration. Final Rule: Confidentiality of Substance Use Disorder Patient Records (Part 2 update). Federal Register, February 16, 2024.
9. Drug Enforcement Administration. Expansion of Buprenorphine Treatment via Telemedicine Encounter. Federal Register, January 17, 2025.
10. 117th Congress. Consolidated Appropriations Act, 2023, Public Law 117-328 — Section 1262 (Mainstreaming Addiction Treatment Act of 2023).
11. Substance Abuse and Mental Health Services Administration. FindTreatment.gov — the federal locator for licensed substance use treatment, including OTPs.